Author:
Ceriello Antonio,Hussain Akhtar
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference8 articles.
1. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE- ONE trial;Heerspink;Diab Res Clin Pract,2023
2. Type 1 diabetes and cardiovascular disease;Schnell;Cardiovascular Diabetology,2013
3. Heerspink HJ, Cherney DZ, Groop PH, Matthieu C, Rossing P, Tuttle KR, McGill JB. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol 2023; 11:5 36-40. doi: 10.1016/S2213-8587(23)00097-9.
4. Report: new cardiovascular, kidney, and glycemic outcomes;Schnell;Cardiovascular Diabetology,2022
5. Glucose -lowering therapies in patients with type 2 diabetes and cardiovascular diseases;Prattichizzo;Eur J Prev Cardiol,2019